Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lifeward Ltd.LFWD · Entity 7620 | Director | August 20, 2026 | August 24, 2026 |
| ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311 | Chief Financial Officer | October 01, 2026 | October 02, 2026 |
| Tessera Defense & Homeland Security Inc.PHGE · Entity 8384 | Interim CFO | December 06, 2023 | December 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lifeward Ltd.
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, no par value per shareSEC Table I · non-derivative | Direct | 13,643 |
Reported balance
After 2026-08-20 transaction · row 1
1 source rowRow 1 · 2026-08-20 · Grant · Acquired 13,643 · Balance 13,643 F1: Represents 13,643 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on August 20, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments commencing from the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 13,643 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on August 20, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments commencing from the Grant Date.
ORAMED PHARMACEUTICALS INC.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 861,076 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 20,000 · Balance 861,076 F1: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Tessera Defense & Homeland Security Inc.
Report date December 06, 2023 · Filed December 11, 2023
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 21:19 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | SaleCommon Stock | 20,000 | $4.51 | $90,200.00 |
DisclosureSEC source: 0001213900-26-106531 · ownership.xml · nonDerivative · entry 1 Gabay Avraham · CIK 0001777328 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 861,076 F1 · shares: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 209,291 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-103535 · ownership.xml · nonDerivative · entry 1 Gabay Avraham · CIK 0001777328 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 881,076 F1 · price: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan. Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 21:08 UTC | Lifeward Ltd. LFWD · Entity 7620 | GrantOrdinary Shares, no par value per share | 13,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-004241 · ownership.xml · nonDerivative · entry 1 Gabay Avraham · CIK 0001777328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,643 F1 · shares: Represents 13,643 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on August 20, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments commencing from the Grant Date. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | SaleCommon Stock | 73,360 | $4.51 | $330,743.56 |
DisclosureSEC source: 0001213900-26-075069 · ownership.xml · nonDerivative · entry 1 Gabay Avraham · CIK 0001777328 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 671,785 F1 · shares: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.255 to $4.750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 21:45 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 95,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-031011 · ownership.xml · nonDerivative · entry 1 Gabay Avraham · CIK 0001777328 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 745,145 F1 · shares: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer. F1 · price: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer. Read SEC document |
| January 22, 2026 Filed Jan 29, 2026 21:05 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionPerformance Stock Units · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-009476 · ownership.xml · derivative · entry 2 Gabay Avraham · CIK 0001777328 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting. F2 · derivative.exercise_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria. F2 · derivative.expiration_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria. Read SEC document |
| January 22, 2026 Filed Jan 29, 2026 21:05 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionCommon Stock | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-009476 · ownership.xml · nonDerivative · entry 1 Gabay Avraham · CIK 0001777328 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 649,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting. F1 · price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting. Read SEC document |
| December 31, 2025 Filed Jan 3, 2026 01:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantPerformance Stock Units · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-000658 · ownership.xml · derivative · entry 3 Gabay Avraham · CIK 0001777328 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F3 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria. F3 · derivative.exercise_date: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria. F3 · derivative.expiration_date: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria. Read SEC document |
| December 31, 2025 Filed Jan 3, 2026 01:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-000658 · ownership.xml · nonDerivative · entry 2 Gabay Avraham · CIK 0001777328 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 630,256 F2 · shares: Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. F2 · price: Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. Read SEC document |
| December 31, 2025 Filed Jan 3, 2026 01:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 81,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-000658 · ownership.xml · nonDerivative · entry 1 Gabay Avraham · CIK 0001777328 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 515,256 F1 · shares: Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. F1 · price: Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 21:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-012238 · ownership.xml · nonDerivative · entry 2 Gabay Avraham · CIK 0001777328 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,040 F2 · shares: Represents shares issued on settlement of PSUs previously granted on January 2, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 21:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-012238 · ownership.xml · nonDerivative · entry 1 Gabay Avraham · CIK 0001777328 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392,040 F1 · shares: Represents shares issued on settlement of performance stock units ("PSUs") previously granted on June 20, 2024 that vested on February 11, 2025 based on the achievement of the applicable performance criteria. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:10 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 188,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-001166 · ownership.xml · nonDerivative · entry 1 Gabay Avraham · CIK 0001777328 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,040 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 15,666 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-095932 · ownership.xml · nonDerivative · entry 1 Gabay Avraham · CIK 0001777328 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,040 F1 · price: Represents a grant of 30,000 Restricted Stock Units ("RSUs") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 20:15 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 140,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-054781 · ownership.xml · nonDerivative · entry 1 Gabay Avraham · CIK 0001777328 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Represents a grant of 140,040 Restricted Stock Units ("RSUs"), of which 93,360 will vest on June 18, 2026 and the remaining 46,680 will vest in four equal quarterly installments of 11,670 starting September 18, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| February 03, 2021 Filed Feb 8, 2021 22:29 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001213900-21-007494 · ownership.xml · derivative · entry 1 Gabay Avraham · CIK 0001777328 · CFO, Treasurer and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-02-03 F1 · kind: The Stock Option will vest in 4 equal installments as follows: 10,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments as follows: 10,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 22:06 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 33,146 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001213900-19-018197 · ownership.xml · derivative · entry 2 Gabay Avraham · CIK 0001777328 · CFO, Treasurer and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,146 Underlying: Common Stock · 33,146 shares Expires 2029-09-12 F1 · kind: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on June 17, 2019 and provides for vesting in 4 installments as follows: 5,396 shall vest on December 31, 2019; and 9,250 shall vest on each of December 31, 2020, December 31, 2021 and December 31, 2022. F1 · derivative.exercise_date: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on June 17, 2019 and provides for vesting in 4 installments as follows: 5,396 shall vest on December 31, 2019; and 9,250 shall vest on each of December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| June 17, 2019 Filed Jun 27, 2019 20:20 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 33,146 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001213900-19-011646 · ownership.xml · derivative · entry 1 Gabay Avraham · CIK 0001777328 · CFO, Treasurer and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,146 Underlying: Common Stock · 33,146 shares Expires 2029-06-17 F1 · derivative.exercise_date: The Stock Option will vest in 4 installments as follows: 5,396 shall vest on December 31, 2019; and 9,250 shall vest on each of December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| June 17, 2019 Filed Sep 16, 2019 22:06 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock Option (right to buy) · Derivative | 33,146 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001213900-19-018197 · ownership.xml · derivative · entry 1 Gabay Avraham · CIK 0001777328 · CFO, Treasurer and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,146 shares Expires 2029-06-17 F1 · kind: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on June 17, 2019 and provides for vesting in 4 installments as follows: 5,396 shall vest on December 31, 2019; and 9,250 shall vest on each of December 31, 2020, December 31, 2021 and December 31, 2022. F1 · derivative.exercise_date: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on June 17, 2019 and provides for vesting in 4 installments as follows: 5,396 shall vest on December 31, 2019; and 9,250 shall vest on each of December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.